These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28002201)

  • 21. Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.
    Simon JA; Maamari RV
    Climacteric; 2013 Aug; 16 Suppl 1():37-43. PubMed ID: 23848490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estradiol absorption from vaginal tablets in postmenopausal women.
    Notelovitz M; Funk S; Nanavati N; Mazzeo M
    Obstet Gynecol; 2002 Apr; 99(4):556-62. PubMed ID: 12039110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.
    Pinkerton JV; Shifren JL; La Valleur J; Rosen A; Roesinger M; Siddhanti S
    Menopause; 2003; 10(1):45-52. PubMed ID: 12544676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
    Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
    Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.
    Jensen JT; Edelman AB; Chen BA; Archer DF; Barnhart KT; Thomas MA; Burke AE; Westhoff CL; Wan LS; Sitruk-Ware R; Kumar N; Variano B; Blithe DL
    Contraception; 2018 May; 97(5):422-427. PubMed ID: 29409834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women.
    Mitchell CM; Guthrie KA; Larson J; Diem S; LaCroix AZ; Caan B; Shifren JL; Woods NF; Heiman JR; Lindau ST; Reed SD
    Menopause; 2019 Aug; 26(8):816-822. PubMed ID: 30994576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy.
    Bouchard C; Labrie F; Archer DF; Portman DJ; Koltun W; Elfassi É; Grainger DA; Ayotte N; Cooper TA; Martens M; Waldbaum AS; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
    Climacteric; 2015; 18(4):590-607. PubMed ID: 25511551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
    Archer DF; Labrie F; Montesino M; Martel C
    J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women.
    Tucker KM; Godha K; Mirkin S; Archer DF
    Menopause; 2018 Jul; 25(7):762-766. PubMed ID: 29509598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of estradiol vaginal gel on vaginal atrophy in postmenopausal women: A randomized double-blind controlled trial.
    Tanmahasamut P; Jirasawas T; Laiwejpithaya S; Areeswate C; Dangrat C; Silprasit K
    J Obstet Gynaecol Res; 2020 Aug; 46(8):1425-1435. PubMed ID: 32715556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study.
    Eriksen PS; Rasmussen H
    Eur J Obstet Gynecol Reprod Biol; 1992 Apr; 44(2):137-44. PubMed ID: 1587379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
    Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
    Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
    Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
    J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy.
    Bruyniks N; Biglia N; Palacios S; Mueck AO
    Climacteric; 2017 Jun; 20(3):195-204. PubMed ID: 28267367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
    Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
    Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial Comment on "TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial".
    Leeners B
    J Sex Med; 2016 Dec; 13(12):1938-1939. PubMed ID: 27914564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.